Search
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigational[A264953] On January 30, 2025, suzetrigine was approved by the FDA as a first-in-class non-opioid analgesic.[L52098]
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalMBL forms different oligomers but must form at least a tetramer to be active. … rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).
Gepirone
go.drugbank.com/drugs/DB12184Approved[A261670,A261675,A182315] Gepirone was approved by the FDA on September 28, 2023, under the brand name EXXUA for the treatment of adults with major depressive disorder.
Caspofungin
go.drugbank.com/drugs/DB00520ApprovedInvestigationalIt shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. … Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc.
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Ferric sulfate
go.drugbank.com/drugs/DB11171ApprovedIt is produced by the reaction of sulfuric acid and an oxidizing agent. … [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003]
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.
Ganirelix
go.drugbank.com/drugs/DB06785ApprovedInvestigational[A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]
Prademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering